智通财经APP获悉，荃信生物-B(02509)早盘涨超9%。截至发稿，涨5.60%，报17.15港元，成交额2670.93万港元。
消息面上，荃信生物中期财报显示，公司BD成果集中兑现。上半年4.24亿营业收入中，授权协议总收入达3.79亿元，主要包括TSLP/IL-13双抗QX027N海外授权的首付款及非现金对价、TSLP单抗QX008N里程碑付款、和TSLP/IL-33双抗QX031N里程碑付款。
华创证券指出，"荃信1.0"单抗产品布局成果逐步显现。首个商业化产品乌司奴单抗生物类似药赛乐信®/赛捷宁®（QX001S）销售势头强劲，其商业化伙伴在2026年上半年录得国内销售额逾3亿元，已超过去年全年水平，公司从中获得的产品供应及利润分成总收入超过4950万元；5月，克罗恩病（CD）适应症获批。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.